The Latest From Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Brigatinib

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) took the opportunity at the 2016 American Society of Clinical Oncology (ASCO) meeting over the weekend to present updated clinical data on brigatinib. The data was from the trial of the compound on ALK+ patients with advanced non-small cell lung cancer (NSCLC).

Story continues below

In a press release, Ariad Pharmaceuticals said that the data it was presenting at ASCO contained more mature safety and efficacy data on the brigatinib trial. The data highlighted the median duration of response as well as the response rate.

Ariad said that it enrolled 137 patients for the study to assess the safety and efficacy of the therapy. The ALK+ NSCLC patients enrolled in the trial were 79 and all but only eight of them had failed previous treatment with crizotinib.

Median survival rate

According to Ariad, the response rate of brigatinib in ALK+ NSCLC patients who had previously failed crizotinib was 72%. The compound demonstrated substantial anti-tumor activity in that patient group.

It was reported that the median progression-free survival was more than one year in the post-crizotinib ALK+ NSCLC patient group. The median survival duration noted with brigatinib had not been achieved in patients who didn’t previously receive crizotinib treatment.

Activity of the compound

Ariad further said that 72% of the ALK+ NSCLC patients who had previously received crizotinib therapy showed an objective response when brigatinib was administered. The company said that at least 62% of the objective response had been confirmed.

Additionally, 80% of the 25 patients who received 180 mg dose regimen showed an objective response and 76% of those cases were confirmed. Of the eight patients who had positively responded to crizotinib, 100% of them showed an objective response and all those cases were confirmed.

More outcome details

According to Ariad, almost all ALK+ NSCLC patients demonstrated tumor shrinkage with 21 of the patients showing 100% shrinkage in their tumor, in other words complete response. The company further said that median duration of response in all the confirmed responders was 14.5 months when anaylized in ALK+ NSCLC patients who had prior crizotinib therapy.

No fresh safety signals had emerged at the time of the latest follow-up.

An ad to help with our costs